Elanco Animal Health Incorporated

Registration Deadline:

12/06/2024

Submit Your Information

A securities class action has been filed in the USDC — MD. against Elanco Animal Health Incorporated (ELAN) (“Elanco” or the “Company”), on behalf of all persons or entities that purchased or otherwise acquired Elanco 28 securities between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”).

 

Elanco is an animal health company that develops, manufactures, and markets products for pets and farm animals. The Company is developing, inter alia, Zenrelia, a “safe, highly effective, and convenient” once-daily oral Janus kinase (“JAK”) inhibitor for canine dermatology, and Credelio Quattro, a broad spectrum parasiticide product for dogs.

 

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:

1. Zenrelia was less safe than the Company had led investors to believe;

2. Elanco was unlikely to meet its own previously issued timeline for the U.S. approval and commercial launch of both Zenrelia and Credelio Quattro;

3. accordingly, the Company’s business and/or financial prospects were overstated; and

4. as a result, the Elanco’s public statements were materially false and misleading at all relevant times, thereby harming investors.

 

After the Company’s press release on June 27, 2024, Elanco’s stock price fell $3.69 per share, to close at $14.28 per share on the same day.

 

If you purchased Elanco securities during the class period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.

 

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors

If you suffered a loss on your investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.